Browse our anti-CYLD (CYLD) Antibodies

On www.antibodies-online.com are 79 Cylindromatosis (Turban Tumor Syndrome) (CYLD) Antibodies from 18 different suppliers available. Additionally we are shipping CYLD Kits (9) and CYLD Proteins (8) and many more products for this protein. A total of 99 CYLD products are currently listed.
Synonyms:
2010013M14Rik, 2900009M21Rik, BRSS, C130039D01Rik, CDMT, cyld, CYLD1, CYLDI, EAC, LRRGT00003, MFT, MFT1, mKIAA0849, Rp1, Rp1h, SBS, TEM, USPL2
list all antibodies Gene Name GeneID UniProt
CYLD 100362727  
CYLD 74256 Q80TQ2
CYLD 1540 Q9NQC7

Most Popular Reactivities for anti-CYLD (CYLD) Antibodies

anti-Rat (Rattus) CYLD Antibodies:

anti-Mouse (Murine) CYLD Antibodies:

anti-Human CYLD Antibodies:

All available anti-CYLD Antibodies

Go to our pre-filtered search.

More Antibodies against CYLD Interaction Partners

Zebrafish Cylindromatosis (Turban Tumor Syndrome) (CYLD) interaction partners

  1. The crystal structures representing the catalytic states of zebrafish CYLD for Met1 (show DNMT1 Antibodies)- and Lys63-linked Ub chains and two distinct precatalytic states for Met1 (show DNMT1 Antibodies)-linked chains are presented.

Mouse (Murine) Cylindromatosis (Turban Tumor Syndrome) (CYLD) interaction partners

  1. TLR4 (show TLR4 Antibodies) activates CASPASE-8 (show CASP8 Antibodies) to cleave and remove the deubiquitinase cylindromatosis (CYLD) in a TRIF (show RNF138 Antibodies)- and RIPK1 (show RIPK1 Antibodies)-dependent manner to disable necroptosis in macrophages.

  2. CYLD contributes to the transdifferentiation of adventitial fibroblasts via deubiquitinating Nox4 (show NOX4 Antibodies) and may play a role in vascular remodeling.

  3. this study shows that by polarization of the T cell cytokine response, CYLD can favor the development of allergic airway disease

  4. Our findings underscore a critical tumor-suppressing role for functional intestinal epithelial CYLD in colitis-associated carcinogenesis

  5. Deubiquitinase CYLD negatively regulates MyD88 (show MYD88 Antibodies)-mediated signaling by directly interacting with MyD88 (show MYD88 Antibodies) and deubiquitinating nontypeable Haemophilus influenzae (NTHi)-induced K63-linked polyubiquitination of MyD88 (show MYD88 Antibodies) at lysine 231.

  6. CYLD interrupts the ERK (show EPHB2 Antibodies)- and p38 (show CRK Antibodies)-/AP-1 (show JUN Antibodies) and c-Myc (show MYC Antibodies) pathways to suppress Nrf2 (show NFE2L2 Antibodies)-operated antioxidative capacity, thereby enhancing oxidative stress in the heart.

  7. Our data demonstrate that inefficient negative selection in the thymus of CYLD(ex7/8) mice result from a defect in mTEC maturation.

  8. The deubiquitinating enzyme CYLD controls apical docking of basal bodies in ciliated epithelial cells.

  9. Data show that the in utero death of NF-NF (show NFASC Antibodies)-kappaB (show NFKB1 Antibodies) essential modulator (NEMO (show IKBKG Antibodies)) and cylindromatosis protein double mutant mice is mediated by TNF (show TNF Antibodies) receptor 1 (TNFR1 (show TNFRSF1A Antibodies)) signaling and can be rescued by TNFR1 (show TNFRSF1A Antibodies) deficiency.

  10. CYLD is a central regulator of apoptotic cell death in murine hepatocytes by controlling NF-kappaB (show NFKB1 Antibodies) dependent anti-apoptotic signaling.

Human Cylindromatosis (Turban Tumor Syndrome) (CYLD) interaction partners

  1. The data reveal SPATA2 (show SPATA2 Antibodies) as a high-affinity binding partner of CYLD and HOIP (show RNF31 Antibodies), and a regulatory component of linear ubiquitin chain assembly complex-mediated NF-kappaB (show NFKB1 Antibodies) signaling.

  2. The current investigations identified a subset of HPV-positive HNSCCs with mutations in the genes TRAF3 (show TRAF3 Antibodies) (tumor necrosis factor (show TNF Antibodies) receptor-associated factor 3) and CYLD (cylindromatosis lysine 63 deubiquitinase). Defects in TRAF3 (show TRAF3 Antibodies) and CYLD correlated with the activation of transcriptional factor nuclear factor kappaB, episomal HPV status of tumors, and improved patient survival.

  3. The predicted PUB domain in the N-terminus of SPATA2 interacts with the USP domain of CYLD and SPATA2 is required for recruitment of CYLD to the TNF-alpha receptor-associated signaling complexes.

  4. STAT3 (show STAT3 Antibodies) and miR (show MLXIP Antibodies)-181b control each other's expression in a positive feedback loop that regulates SFCs via CYLD pathway.

  5. CYLD Promotes TNF-alpha (show TNF Antibodies)-Induced Cell Necrosis Mediated by RIP-1 (show UQCRFS1 Antibodies) in Human Lung Cancer Cells

  6. Low CYLD expression is associated with hepatocellular carcinoma.

  7. miR20a directly repressed the expression of CYLD, leading to activation of the NFkappaB (show NFKB1 Antibodies) pathway and the downstream targets, livin (show BIRC7 Antibodies) and survivin (show BIRC5 Antibodies), which potentially induced GC chemoresistance.

  8. Data show that cylindromatosis (CYLD) overexpression and livin (show BIRC7 Antibodies) knockdown might improve gemcitabine chemosensitivity by decreasing autophagy and increasing apoptosis in bladder cancer (BCa (show BLNK Antibodies)) cells.

  9. aberrantly expressed miR (show MLXIP Antibodies)-130b may regulate cell apoptosis and proliferation of human gastric cancer cells via CYLD, which appears to be a promising therapeutic target for gastric cancer

  10. These results demonstrate the involvement of histone deacetylases in the down regulation of Cyld expression in hepatocellular carcinoma cells.

CYLD Antigen Profile

Antigen Summary

This gene is encodes a cytoplasmic protein with three cytoskeletal-associated protein-glycine-conserved (CAP-GLY) domains that functions as a deubiquitinating enzyme. Mutations in this gene have been associated with cylindromatosis, multiple familial trichoepithelioma, and Brooke-Spiegler syndrome. Alternate transcriptional splice variants, encoding different isoforms, have been characterized.

Alternative names and synonyms associated with CYLD

  • cylindromatosis (turban tumor syndrome) (CYLD) antibody
  • cylindromatosis (turban tumor syndrome), a (cylda) antibody
  • ubiquitin carboxyl-terminal hydrolase CYLD (LOC100362727) antibody
  • cylindromatosis (turban tumor syndrome) (Cyld) antibody
  • 2010013M14Rik antibody
  • 2900009M21Rik antibody
  • BRSS antibody
  • C130039D01Rik antibody
  • CDMT antibody
  • cyld antibody
  • CYLD1 antibody
  • CYLDI antibody
  • EAC antibody
  • LRRGT00003 antibody
  • MFT antibody
  • MFT1 antibody
  • mKIAA0849 antibody
  • Rp1 antibody
  • Rp1h antibody
  • SBS antibody
  • TEM antibody
  • USPL2 antibody

Protein level used designations for CYLD

cylindromatosis (turban tumor syndrome) , probable ubiquitin carboxyl-terminal hydrolase CYLD-like , ubiquitin carboxyl-terminal hydrolase CYLD , deubiquitinating enzyme CYLD , ubiquitin thioesterase CYLD , ubiquitin thiolesterase CYLD , ubiquitin-specific-processing protease CYLD , probable ubiquitin carboxyl-terminal hydrolase CYLD , retinitis pigmentosa 1 homolog , ubiquitin specific peptidase like 2

GENE ID SPECIES
100050308 Equus caballus
556823 Danio rerio
100467467 Ailuropoda melanoleuca
100547998 Meleagris gallopavo
100362727 Rattus norvegicus
74256 Mus musculus
312937 Rattus norvegicus
1540 Homo sapiens
611649 Canis lupus familiaris
536421 Bos taurus
415725 Gallus gallus
Selected quality suppliers for anti-CYLD (CYLD) Antibodies
Did you look for something else?